Key Laboratory of Experimental Animal and Safety Evaluation, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang 310013, P.R. China.
Department of Clinical Laboratory Medicine, Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, P.R. China.
Mol Med Rep. 2017 Dec;16(6):7879-7889. doi: 10.3892/mmr.2017.7641. Epub 2017 Sep 27.
The platelet‑derived growth factor (PDFG) signaling pathway exerts persistent activation in response to a variety of stimuli and facilitates the progression of hepatic fibrosis. Since this pathway modulates a broad spectrum of cellular processes, including cell growth, differentiation, inflammation and carcinogenesis, it has emerged as a therapeutic target for hepatic fibrosis and liver‑associated disorders. The present review exhibits the current knowledge of the role of the PDGF signaling pathway and its pathological profiles in hepatic fibrosis, and assesses the potential of inhibitors which have been investigated in the experimental hepatic fibrosis model, in addition to the clinical challenges associated with these inhibitors.
血小板衍生生长因子（PDGF）信号通路对各种刺激物产生持续激活作用，促进肝纤维化的进展。由于该通路调节广泛的细胞过程，包括细胞生长、分化、炎症和癌变，因此它已成为肝纤维化和与肝脏相关疾病的治疗靶点。本综述展示了 PDGF 信号通路及其在肝纤维化中的病理特征的最新知识，并评估了在实验性肝纤维化模型中研究的抑制剂的潜力，以及与这些抑制剂相关的临床挑战。
